Mei Sakuma et al. suggested that the change of CD45RA − CD27 + CD127 + central memory T cells frequency during nivolumab treatment might be a biomarker for predicting its therapeutic effect on esophageal squamous cell carcinoma patients [26]. The gene discussed is CD27; the disease is esophageal squamous cell carcinoma.